Crossmark

siRNA screen identifies QPCT as a druggable target for Huntington's disease

Crossref DOI link: https://doi.org/10.1038/nchembio.1790

Published Online: 2015-04-06

Published Print: 2015-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jimenez-Sanchez, Maria

Lam, Wun

Hannus, Michael

Sönnichsen, Birte

Imarisio, Sara

Fleming, Angeleen

Tarditi, Alessia

Menzies, Fiona

Ed Dami, Teresa

Xu, Catherine

Gonzalez-Couto, Eduardo

Lazzeroni, Giulia

Heitz, Freddy

Diamanti, Daniela

Massai, Luisa

Satagopam, Venkata P

Marconi, Guido

Caramelli, Chiara

Nencini, Arianna

Andreini, Matteo

Sardone, Gian Luca

Caradonna, Nicola P

Porcari, Valentina

Scali, Carla

Schneider, Reinhard

Pollio, Giuseppe

O'Kane, Cahir J https://orcid.org/0000-0002-3488-2078
Caricasole, Andrea

Rubinsztein, David C
License Information

Text and Data Mining valid from 2015-04-06
More Information

Article History

Received: 14 August 2014

Accepted: 5 March 2015

First Online: 6 April 2015

Competing interests

: A.T., E.G.-C., G.L., F.H., D.D., L.M., G.P., G.M., C.C., A.N., M.A., G.L.S., N.P.C., V.P., C.S. and A.C. were employed by Siena Biotech; M.H. and B.S. were employed by Cenix BioScience GmbH.